<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02253810</url>
  </required_header>
  <id_info>
    <org_study_id>2014-115</org_study_id>
    <nct_id>NCT02253810</nct_id>
  </id_info>
  <brief_title>Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy</brief_title>
  <official_title>The Effect of Intravenous Tranexamic Acid on Blood Loss and Transfusion After Periacetabular Osteotomy: a Prospective, Double-blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this randomized controlled, double-blinded trial is to assess the efficacy of&#xD;
      intravenous tranexamic acid, a drug, in reducing blood loss and transfusion in patients&#xD;
      undergoing periacetabular osteotomy, an elective reorientation procedure for the hip joint.&#xD;
      The investigators hypothesize that tranexamic acid will be more effective than placebo&#xD;
      (normal saline solution) in reducing blood loss and transfusion after periacetabular&#xD;
      osteotomy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Periacetabular osteotomy (PAO) is an elective reorientation surgery for the hip joint,&#xD;
      typically for the treatment of hip dysplasia in young, otherwise healthy patients, which&#xD;
      requires multiple pelvic osteotomies around the acetabulum. A major source of its&#xD;
      perioperative morbidity is blood loss. The principal cause of postoperative blood loss after&#xD;
      PAO is surgical trauma, with secondary activation of both the coagulation cascade and local&#xD;
      fibrinolysis. In the PAO literature, allogeneic transfusion rates are as high as 58%, and&#xD;
      blood loss can range to nearly 4 L. The risk of excessive blood loss and blood transfusion in&#xD;
      young, healthy patients after elective surgery is an event that can be reduced with blood&#xD;
      conservation protocols, which can include pharmacological agents. Tranexamic acid is a&#xD;
      synthetic derivative of the amino acid lysine and a competitive inhibitor of plasminogen&#xD;
      activation that interferes with fibrinolysis. Multiple studies and meta-analyses have shown&#xD;
      that intravenous administration of the antifibrinolytic agent tranexamic acid reduces&#xD;
      postoperative bleeding and the need for transfusion during joint replacement surgery.&#xD;
      However, no published data exists to support its use during PAO. We hypothesize that&#xD;
      intravenous tranexamic acid will reduce perioperative blood loss and, thus, transfusion&#xD;
      requirement in patients undergoing PAO. A total of 80 patients will be enrolled. Patients&#xD;
      will be randomized to receive either intravenous tranexamic acid versus placebo (normal&#xD;
      saline) during PAO. Calculated total blood loss (primary outcome) will be determined, and&#xD;
      intraoperative cell saver utilization (secondary outcome), and (3) postoperative allogeneic&#xD;
      blood transfusion (secondary outcome) will be recorded. Patients will be followed for a total&#xD;
      of 6 weeks after surgical intervention. If the use of IV tranexamic acid in the PAO patient&#xD;
      population significantly reduces total perioperative blood loss, then it would provide an&#xD;
      efficacious and inexpensive method for reducing postoperative morbidity after PAO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calculated Total Blood Loss</measure>
    <time_frame>1day (Hospital Admission)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allogenic Blood Transfusion</measure>
    <time_frame>1day (Hospital Admission)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Dysplasia, Congenital Hip</condition>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 12 years old&#xD;
&#xD;
          -  Age less than or equal to 45 years old&#xD;
&#xD;
          -  Indicated for elective periacetabular osteotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative use of an anticoagulant (Plavix, warfarin, lovenox, etc.)&#xD;
&#xD;
          -  History of hypersensitivity to tranexamic acid&#xD;
&#xD;
          -  History of thromboembolic event (e.g., Pulmonary embolism or Deep vein thrombosis)&#xD;
&#xD;
          -  History of subarachnoid hemorrhage&#xD;
&#xD;
          -  History or evidence of hepatic dysfunction (aspartate transaminase-alanine&#xD;
             transaminase ratio greater than 60) or renal dysfunction (Creatinine greater than 1.5&#xD;
             mg/dL, or glomerular filtration rate less than 30 mL/minute)&#xD;
&#xD;
          -  History of seizure&#xD;
&#xD;
          -  Coronary stents or prior diagnosis of coronary artery disease&#xD;
&#xD;
          -  Color blindness&#xD;
&#xD;
          -  Leukemia&#xD;
&#xD;
          -  Congenital or acquired coagulopathy as evidence by international normalized ratio&#xD;
             (INR) greater than 1.4 or partial thromboplastin time (PTT) &gt; 1.4 times normal, or&#xD;
             Platelets less than 150,000/mm^3 on preoperative laboratory testing&#xD;
&#xD;
          -  Use of hormone replacement therapy or hormonal contraceptive agent within 7 days prior&#xD;
             to surgery&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Donated preoperative autologous blood&#xD;
&#xD;
          -  Younger than 12-years-old and older than 45-years-old&#xD;
&#xD;
          -  Preoperative hemoglobin less than 10 g/dL&#xD;
&#xD;
          -  Concomitant open procedures (e.g., femoral osteotomy or osteochondral allograft)&#xD;
&#xD;
          -  Patients with any contraindication to neuraxial anesthesia:&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  History of lumbar spinal fusion&#xD;
&#xD;
          -  Infection at the site of the epidural&#xD;
&#xD;
          -  Coagulopathy, as defined above&#xD;
&#xD;
          -  Ventriculoperitoneal shunt&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest L. Sink, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>September 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2014</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysplasia, Congenital Hip</keyword>
  <keyword>Osteotomy</keyword>
  <keyword>Blood Transfusion</keyword>
  <keyword>Tranexamic Acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Developmental Dysplasia of the Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 26, 2019</submitted>
    <returned>December 13, 2019</returned>
    <submitted>May 4, 2021</submitted>
    <returned>May 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

